Mesotelioma pleural maligno (MPM)
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | DIS-MESOTHELIOMA |
|---|---|
| Tipo | Enfermedad |
| Aliaces | Mesotelioma malignoMesotelioma NOSMesotelioma peritonealЗлоякісна мезотеліома плеври |
| Situación | reviewed 2026-05-04 | pending_clinical_signoff |
| Enfermedades | Ninguna declarada |
| Fuentes | Ninguna declarada |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 9050/3 |
|---|---|
| icd_o_3_topography | ["C38.4", "C48.1", "C48.2"] |
| icd_10 | C45.0 |
| who_classification | WHO Thoracic Tumours 5th ed (2021): Mesothelioma |
Notas
Malignant mesothelioma is predominantly a pleural cancer (MPM ~80% of cases); peritoneal mesothelioma (~20%) has different treatment (cytoreductive surgery + hyperthermic intraperitoneal chemotherapy [HIPEC] for peritoneal). This disease entity focuses on MPM. Historically extremely poor prognosis (mOS ~12 mo); CheckMate-743 (FDA 2020) with nivolumab+ipilimumab improved mOS to 18.1 mo — first new 1L approval in 15 years. BAP1 IHC loss is a diagnostic marker (not actionable therapeutically). PD-L1 expression is not validated as predictive for ICI benefit in MPM.
Utilizado por
Algoritmos
ALGO-HEREDITARY-MELANOMA-SURVEILLANCE- ALGO-HEREDITARY-MELANOMA-SURVEILLANCEALGO-MESOTHELIOMA-1L- ALGO-MESOTHELIOMA-1LALGO-MESOTHELIOMA-2L- ALGO-MESOTHELIOMA-2L
Enfermedad
DIS-NSCLC- Non-small cell lung cancer
Indicación
IND-BAP1-CARRIER-INTENSIFIED- IND-BAP1-CARRIER-INTENSIFIEDIND-BAP1-CARRIER-SURVEILLANCE- IND-BAP1-CARRIER-SURVEILLANCEIND-MESOTHELIOMA-1L-NIVO-IPI- IND-MESOTHELIOMA-1L-NIVO-IPIIND-MESOTHELIOMA-1L-PEMETREXED-PLATINUM- IND-MESOTHELIOMA-1L-PEMETREXED-PLATINUMIND-MESOTHELIOMA-2L-NIVO- IND-MESOTHELIOMA-2L-NIVO
Cuestionarios
QUEST-MESOTHELIOMA-1L-STUB- Mesotelioma maligno — primera línea
Señal de alerta
RF-ACTIVE-AUTOIMMUNE-DISEASE-ICI-RISK- Paciente con pre-inmunes o inflamatorias preexistentes activas o incompletas...RF-BAP1-CONFIRMED-CARRIER- Confirmada variante patógena de la línea germinal / patógeno probable en el gen BAP1 — tumor BAP1 p...RF-BAP1-FAMILY-HISTORY-SUSPICION- Pedigree familiar sugestivo del síndrome de predisposición tumoral BAP1 - confirmación de la línea germinal BAP...RF-OCC-ASBESTOS-MALIGNANCY-PREVENTION- Exposición laboral documentada histórica a fibras de amianto (crisotilo, amosita, crocodilo...RF-OCC-FIREFIGHTER-PREVENTION- Exposición profesional histórica documentada como bombero profesional (≥10 años en activo...
Esquema terapéutico
REG-NIVO-IPI-MESOTHELIOMA- Nivolumab + ipilimumab (mesotelioma, 1L)REG-PEMETREXED-CISPLATIN-MPM- Pemetrexed + cisplatin (malignant pleural mesothelioma, 1L)
Fuentes
SRC-CONFIRM-FENNELL-2021- Nivolumab versus placebo en pacientes con recidiva de mesotelioma maligno (CONFIRM): aSRC-EMPHACIS-VOGELZANG-2003- Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in pat...